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AbstrAct
Cancer-selective drug delivery is an important concept in improving treatment 
while minimizing off-site toxicities, and sigma-2 receptors, which are overexpressed 
in solid tumors, represent attractive pharmacologic targets. Select sigma-2 ligands 
have been shown to be rapidly internalized selectively into cancer cells while retaining 
the capacity to deliver small molecules as drug cargoes. We utilized the sigma-2-
based drug delivery concept to convert Erastin, a clinically underperforming drug, 
into a potent pancreatic cancer therapeutic. The Erastin derivative des-methyl Erastin 
(dm-Erastin) was chemically linked to sigma-2 ligand SV119 to create SW V-49. 
Conjugation increased the killing capacity of dm-Erastin by nearly 35-fold in vitro and 
reduced the size of established tumors and doubled the median survival in syngeneic 
and patient-derived xenograft models when compared to non-targeted dm-Erastin. 
Mechanistic analyses demonstrated that cell death was associated with robust reactive 
oxygen species production and could be efficiently antagonized with antioxidants. 
Mass spectrometry was employed to demonstrate selective uptake into pancreatic 
cancer cells. Thus, targeted delivery of dm-Erastin via conjugation to the sigma-2 
ligand SV119 produced efficient tumor control and prolonged animal survival with 
minimal off-target toxicities, and SW V-49 represents a promising new therapeutic 
with the potential to advance the fight against pancreatic cancer. 
IntroductIon
Pancreatic cancer is a devastating disease with a 
5-year survival of only 7% [1]. Surgical intervention 
remains the only potential cure, but only 15 to 20 percent 
of patients are diagnosed early enough to be amenable for 
an attempt at resection [2]. Even in this highly select group 
of patients, the prognosis remains poor due to a high rate 
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of local recurrence and metastatic disease [3]. Treatment 
with standard chemotherapy offers a very modest 
prolongation of life with few, if any, cures [3]. There is 
desperate need to explore novel therapeutics to improve 
outcomes. The clinical need is so marked that Congress 
recently passed the Recalcitrant Cancer Research Act 
specifically to encourage further research into treatments 
for pancreatic cancer. 
Erastin is a small molecule discovered during a 
screen of synthetic compounds with cytotoxic activity 
in cells containing mutations in the KRAS oncogene [4]. 
KRAS mutations are found in more than 90% of pancreatic 
cancers, and despite its frequency and being the earliest 
genetic alteration, previous attempts to selectively target 
KRAS have failed [5, 6]. Erastin has been shown to inhibit 
the cystine/glutamate antiporter (system xc
-), resulting in 
the accumulation of reactive oxygen species (ROS) and 
non-apoptotic cancer cell death [7, 8]. System xc
- permits 
uptake of cystine, which is vital to the formation of 
cysteine, a key building block for the production of the 
antioxidant glutathione, an important contributor to cell 
homeostasis [9]. Additionally, Erastin has been reported 
to target mitochondrial voltage-dependent anion channels 
[10]. These channels are found in the outer mitochondrial 
membrane and facilitate transport of metabolites [11] 
and were reported to be important, but not sufficient, to 
result in Erastin-mediated cell death [10]. Erastin and its 
analogues have been explored in several clinical trials 
but have underperformed [12, 13]. We hypothesized that 
the lack of in vivo efficacy was caused by either a lack 
of targeted drug delivery and/or a failure of an efficient 
uptake mechanism by the cancer cells.
Targeting cytotoxic cancer therapeutics selectively 
to cancer cells represents a highly desired objective with 
potential to improve treatment efficacies and minimize 
off-target toxicities. Over the last decade, our laboratory 
has developed efficient means to selectively deliver 
small molecule drug cargoes into cancer cells based 
on the sigma-2 ligand/receptor concept [14]. We have 
demonstrated sigma-2 receptors to be overexpressed in 
most human malignancies, including pancreatic cancer 
[15]. Sigma-2 ligands have been shown to be rapidly 
internalized into cancer cells [16] and, at high doses, are 
capable of inducing apoptosis [15, 17-19]. Importantly, 
sigma-2 ligand conjugates retain the capacity to bind 
and deliver additional drug cargoes into cancer cells. 
The sigma-2 ligand portion provides targeting while 
the effector molecule provides functionality as part of 
the dual-domain therapeutic [14, 20, 21]. In summary, 
we have previously established proof-of-principal for 
sigma-2 ligand targeted cancer delivery with several small 
molecules, and this work represents the culmination of a 
highly collaborative multi-investigator effort focused on 
developing a new therapeutic with the goal of testing the 
sigma-2 cancer delivery concept clinically. 
Herein, we report the synthesis and characterization 
of the novel small molecule drug conjugate SW V-49. This 
dual-domain compound was synthesized as a conjugate 
of the sigma-2 ligand SV119 with des-methyl Erastin 
(dm-Erastin). In these studies, we show that SW V-49 
overcomes the cellular internalization block of dm-Erastin 
and reduces tumor sizes while improving survival in the 
best available models of pancreatic cancer. Our results 
suggest that SW V-49 is a highly potent pancreatic cancer 
therapeutic worthy of clinical investigation. 
results
synthesis of the sigma-2/dm-erastin conjugate 
sW V-49
The main focus of our work was to develop novel 
therapies for evaluation in patients with pancreatic 
cancer. Erastin (Figure 1A) and its analogues are small 
molecules with cancer-selective cytotoxic activity profiles 
in vitro and thus represent attractive candidates for drug 
development [4]. The initial reports on Erastin analogues 
suggested that they might prove effective in pancreatic 
cancer patients, but they underperformed in clinical trials 
[12, 13]. We sought to understand why this drug class 
failed clinically and found that Erastin alone was incapable 
of inducing cell death in AsPC-1 and other pancreatic 
cancer cells in vitro while SYO-1 synovial cancer cells 
were sensitive (Figure 1B). We hypothesized that the 
lack of efficacy in pancreatic cancer might be caused 
by a deficiency in cellular drug uptake/internalization. 
Based on our previous experience utilizing sigma-2 
ligands to deliver a payload to cancer cells [14, 20-22], 
we theorized that uptake blockade could potentially 
be overcome if we chemically conjugated Erastin to 
a sigma-2 ligand. We theorized that the conjugation 
would not sterically interfere with Erastin’s function 
and cancer-selective lethality. An important criteria in 
choosing small molecules for further development into 
dual-domain drug conjugates is accessibility to chemical 
synthesis. The originally described Erastin molecule was 
challenging to synthesize due to an optically active carbon 
atom located within its structure (Figure 1A, asterisk). A 
slightly modified analogue, dm-Erastin, was reported to 
be functionally equivalent to the parental molecule as the 
methyl-substituted carbon is not necessary for its activity, 
thus avoiding the additional optically active structural site 
[23]. Thus, prior to generating the sigma-2/Erastin drug 
conjugate, we synthesized dm-Erastin (Figure 1A) and 
compared it with commercially available Erastin (EMD 
Millipore) in cell viability assays. Both drugs had identical 
cytotoxic activity profiles when assessed on Erastin-
sensitive synovial sarcoma cells (data not shown). As a 
result of these comparisons, dm-Erastin was chemically 
linked to our sigma-2 delivery vehicle SV119 (Figure S1) 
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resulting in the novel drug conjugate SW V-49 (Figure 
1A). 
sW V-49 overcomes the chemotherapeutic plateau 
of dm-erastin via enhanced drug uptake
As previously noted, all of our pancreatic cancer cell 
lines were resistant to Erastin. To test if conjugation to a 
sigma-2 ligand would overcome this treatment resistance, 
PANC-1 cells were treated with SW V-49, SV119 
alone, dm-Erastin alone, and with equimolar mixtures 
of SV119 and dm-Erastin combined. Concentrations 
of dm-Erastin as high as 100 µM failed to demonstrate 
significant cytotoxic effects and its half-maximal killing 
concentration (IC50) was greater than 150 µM (Figure 
2A). The moderate killing profile of the delivery agent 
SV119 was anticipated as reported previously [14, 17, 18]. 
Furthermore, equimolar mixes of dm-Erastin with SV119 
did not lead to a substantial improvement over the baseline 
activity of SV119, as cytotoxicity was nearly identical 
to that of sigma-2 ligand alone (Figure 2A). In stark 
contrast to all other treatment groups, SW V-49 elicited a 
robust cytotoxic response with an IC50 in the single digit 
micromolar range. SW V-49 was 17-fold more effective 
than an equimolar mix of SV119 and dm-Erastin (Figure 
2A, IC50: 4.1 µM ± 0.2 vs 70.0 µM ± 0.3, p < 0.05). This 
in vitro activity profile was confirmed across a panel of 
human- and murine-derived pancreatic cancer cell lines 
(Figure 2B). 
Historically, clinical efficacy has not reliably 
followed success of novel therapies in long cultured 
cancer cell lines, and investigators have postulated that 
genetic drift and adaptation to cell culture conditions 
have contributed to a lack of translatability [24]. Patient-
derived three dimensional cultures (organoids) are thought 
to better predict clinical successes [25, 26]. To assess the 
efficacy of SW V-49 in patient-derived organoid cultures, 
we treated multiple human pancreatic cancer organoid 
cultures (n = 5) with varying doses of SW V-49, SV119, 
and dm-Erastin (Figure 2C). As with the established cell 
lines, we observed a robust response following treatment 
with SW V-49, which resulted in an IC50 of 1.84 µM 
(SEM: ± 1.10). The controls behaved slightly different 
in organoids. The SV119 delivery molecule was nearly 
inactive and dm-Erastin exhibited a small cytotoxic 
response at the highest doses. 
To test whether cellular uptake is improved via 
chemical conjugation with SV119, we utilized mass 
spectrometry and asked if pancreatic cancer cells were 
able to absorb SW V-49 from the culture supernatant when 
compared with non-conjugated dm-Erastin. Based on prior 
studies demonstrating rapid uptake of sigma-2 ligands into 
cancer cells [16], we treated human pancreatic cancer cells 
(MIA PaCa-2) with SW V-49 or dm-Erastin for two hours. 
Figure 1: chemical structures demonstrating the parental compounds and the novel drug conjugate sW V-49. A. The 
parental Erastin molecule (asterisk) and its des-methyl variant are nearly identical structurally. The sigma-2 ligand SV119 was chemically 
conjugated to dm-Erastin, resulting in the sigma-2/dm-Erastin conjugate SW V-49. b. SYO-1 synovial sarcoma cells were treated in a cell 
viability assay to demonstrate that Erastin is functionally active. In contrast, AsPC-1 pancreatic adenocarcinoma cells did not respond to 
Erastin, as demonstrated by lack of cellular death.
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The supernatants and cell pellets were then harvested 
and submitted for mass spectrometry. Drug-containing 
medium in the absence of cells was used to establish the 
baseline signal intensity for the respective compound. 
We found that dm-Erastin did not show any evidence 
for entering the cancer cells, also reflected by the fact 
that the drug concentration in the supernatant remained 
unaltered during the course of the experiment (Figure 2D). 
Extended exposure times and increased drug doses did not 
lead to accumulation of dm-Erastin in the cell pellets. In 
contrast, SW V-49 was found to be associated with the 
cell pellet, while the drug concentration in the supernatant 
fell concomitantly (Figure 2D). These data strongly 
support the hypothesis that the sigma-2 ligand delivery 
moiety of SW V-49 (SV119) is necessary and sufficient to 
facilitate efficient transport across the plasma membrane 
of pancreatic cancer cells, otherwise impermeable for the 
unconjugated drug cargo (dm-Erastin).
sW V-49 reduces tumor growth and improves 
survival in syngeneic and patient-derived 
xenograft models of pancreatic cancer
To determine the in vivo efficacy of SW V-49, we 
employed several murine model systems of pancreatic 
cancer. We utilized genetically-engineered murine models 
driven by a KRAS mutation on a C57BL/6 background 
[27, 28] as well as a patient-derived xenograft model using 
athymic nude mice [29]. In the subcutaneous syngeneic 
model, C57BL/6 mice (n = 15 per group) were observed 
until tumors measured 5-6 mm in diameter and then treated 
with daily i.p. injections of 375 nanomoles of SW V-49, 
SV119, Erastin, an equimolar mix of SV119 and Erastin, 
or vehicle. SW V-49 more than doubled the median 
survival to 48 days (SD: ± 16.9); while vehicle (20.0 ± 8.4 
days), Erastin (18.0 ± 9.2 days), SV119 (19.0 ± 8.6 days), 
and the equimolar mix of SV119 and Erastin (21.0 ± 7.9 
days) all had significantly shorter survivals (Figure 3A, 
p < 0.0001). Only SW V-49 was capable of reducing the 
mean tumor volume during the treatment interval (Figure 
3B, p = 0.0003). None of the other compounds, alone or 
in combination, resulted in a reduction of tumor size and 
all control groups exhibited similar growth rates when 
Figure 2: Conjugation to SV119 overcomes the internalization block of dm-Erastin and increases efficacy in pancreatic 
cancer cell lines. A. PANC-1 cells were treated with increasing concentrations of SW V-49, SV119, Erastin, and an equimolar mix of 
SV119 and Erastin. CellTiter-Glo cell viability assay was performed 24 hours post-treatment. The half-maximal killing activities (IC50) 
of the various treatment conditions are expressed as means (n ≥ 3/group). b. The drug activity profiles (IC50 ± SEM) of SW V-49, Erastin, 
SV119, and the equimolar mix of SV119 and Erastin are shown across multiple pancreatic cancer cell lines (BxPC-3, AsPC-1, MIA PaCa-
2, KCKO). SW V-49 treatment was effective and potent across all cell lines. c. Pancreatic cancer organoids (hM1 [41] is shown) were 
treated with increasing concentrations of SW V-49, SV119, and dm-Erastin. Cell viability was measured 72 hours after treatment using 
CellTiter-Glo. Only treatment with SW V-49 resulted in a robust cytotoxic response (IC50: 1.84 µM ± 1.10). Minimal effect of dm-Erastin 
and SV119 was observed. d. MIA PaCa-2 pancreatic adenocarcinoma cells were exposed to SW V-49 and dm-Erastin for 2 hours. Only 
SW V-49 was decreased from the media supernatant and present in the cell pellet, whereas dm-Erastin remained in the supernatant without 
any significant detection in the cell pellet. 
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compared to vehicle alone (Figure 3B, p = 0.9). 
 Importantly, there were no treatment-related deaths 
or gross abnormalities in mouse behavior. In order to 
assess for more subtle toxicities, serum chemistries (AST, 
ALT, BUN, total protein, glucose, and Cr) and complete 
blood counts were analyzed and there were no significant 
differences (Tables S1 and S2). Necropsy, performed by a 
blinded veterinary pathologist employed by our Digestive 
Diseases Core facility, revealed no difference in mass 
(vehicle: 20.7± 0.6 grams; SW V-49: 21.3 ± 2.1 grams; p 
= 0.600) nor any injury to brain, heart, lungs, alimentary 
tract, kidneys, liver, or pancreas. Only mild peritonitis was 
identified at the site of repeated drug injections. 
SW V-49 was evaluated in patient-derived xenograft 
models of pancreatic cancer, which our group and others 
believe complement the purely murine models [30-32]. 
Thirty mice bearing subcutaneous patient-derived tumors 
were randomized to receive daily treatment with i.p. 
injections of 375 nanomoles of SW V-49 or vehicle control 
for 2 weeks. SW V-49 nearly doubled median survival 
from 33 days (SD: ± 11.5) in the control group to 58 days 
(SD: ± 12.5) in the conjugate-treated group (Figure 3C, 
p = 0.0002). Additionally, SW V-49 markedly slowed 
the growth rate of the established tumors (Figure 3D, p 
< 0.0001). All mice tolerated the treatment well without 
obvious off-target effects.
We compared SW V-49 to a standard treatment 
for pancreatic cancer (gemcitabine) to understand the 
comparative magnitude of our drug’s effect. In addition, 
we evaluated the effectiveness in yet another tumor model. 
The KP-2 tumor line, recently derived from a genetically-
engineered spontaneously-arising model, was implanted 
orthotopically into C57BL/6 mice (n = 5-6 mice/group) 
to assess the efficacy of SW V-49 in a stroma-dense 
model (Figure S2). Similar genetic crosses have been 
demonstrated to recapitulate the tumor microenvironment 
Figure 3: sW V-49 reduces tumor growth and improves median survival in murine models of pancreatic cancer. A. 
C57BL/6 mice (n = 10 mice/group) with established KCKO tumors were treated daily i.p. with 375 nanomoles of the indicated compounds 
for 10 days. Kaplan-Meier survival curve of the mice is shown. Median survival of the group treated with SW V-49 was 48 days (SD: ± 
16.9). All other groups had a significantly lower median survival (***p < 0.001). Mice treated with vehicle, Erastin only, SV 119 only, 
and an equimolar mix of SV119 and Erastin had median survivals of 20.0 ± 8.4 days, 18.0 ± 9.2 days, 19.0 ± 8.6 days, and 21.0 ± 7.9 
days, respectively. b. There was no significant difference between DMSO, SV119, dm-Erastin, and the equimolar mix of SV119 and dm-
Erastin (p = 0.9). Tumor volumes in mice treated with SW V-49 were significantly smaller compared in all control groups (***p < 0.001). 
c. Athymic nude mice (n = 15 mice/group) with established patient-derived xenograft tumors (PDX) were treated daily i.p. with 375 
nanomoles of SW V-49 for 14 days. Mice treated with vehicle served as a control. A Kaplan-Meier survival curve of the mice is shown. 
Median survival of the group treated with SW V-49 was 58 days (SD: ± 12.5) compared to 33 days (SD: ± 11.5) for the control group (***p 
= 0.0002). d. Mice treated with SW V-49 demonstrated a dramatic difference in tumor volume compared to vehicle (****p < 0.0001).
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from the stromal and immunologic perspectives to better 
model the human disease [33, 34]. 
Mice were randomized to receive i.p. injections 
twice weekly of 20 mg/kg gemcitabine or injections daily 
of 200 nanomoles SW V-49 for two weeks. Vehicle was 
utilized as a control. The dosing of SW V-49 was decreased 
to assess for potency with a smaller amount. Mice treated 
with SW V-49 had significantly smaller tumors compared 
to gemcitabine (p = 0.0007) and vehicle (p = 0.0003), 
indicating SW V-49 was effective in a stroma-dense model 
even at lower doses (Figure 4A). These data were repeated 
utilizing a genetically-engineered spontaneously-arising 
tumor line (KCKO) derived by another group [27, 28] via 
implanting tumors subcutaneously into C57BL/6 mice. 
When tumors reached 5-6 mm in diameter, mice were 
treated twice weekly with i.p. injections of 200 nanomoles 
SW V-49, 20 mg/kg gemcitabine, or vehicle alone. Mice 
treated with SW V-49 had significantly smaller tumors 
compared to both gemcitabine (p = 0.049) and vehicle 
groups (Figure 4B, p = 0.047). 
In summary, SW V-49 effectively treated tumors in 
subcutaneous and orthotopic locations and results were 
reproducible in both patient-derived and genetically-
engineered murine models. SW V-49 demonstrated 
efficacy without measurable toxicity and outperformed 
gemcitabine, a clinical standard for the treatment of 
pancreatic cancer. 
sW V-49 competes for the sigma-2 receptor with 
known sigma-2 binders and activates cargo-
specific signaling pathways
SW V-49 is a new chemical entity, and it is highly 
unlikely that our conjugate should enter a cancer cell 
without utilizing the sigma-2 ligand/receptor complex. It 
would also be unexpected that SW V-49 should develop 
an entirely new mechanism of action. For completeness, 
we sought to confirm that SW V-49 binds to the sigma-2 
receptor and retains Erastin’s main mechanism of action. 
In order to demonstrate that SW V-49 binds to the sigma-2 
receptor, we performed a competition assay with SW120, 
a fluorescently-labeled sigma-2 ligand [35], as previously 
described [21]. SW V-49 was able to block uptake of 
SW120 in a dose-dependent fashion (Figure 5A).
We further sought to verify that the mechanism 
of Erastin was preserved after conjugation to SV119. 
Erastin has been shown to initiate ROS-dependent cell 
death via blockade of the cystine/glutamate antiporter 
(system xc
-) [7]. To elucidate the impact of our conjugate 
on the uptake of cystine, AsPC-1 cells were treated 
for three minutes with SV119, Erastin, an equimolar 
combination of SV119 and Erastin, and SW V-49. Cellular 
cystine uptake was monitored via scintillography using 
radiolabeled cystine. SV119 exhibited minimal impact on 
the uptake profile of radiolabeled cystine. Erastin alone 
had the anticipated effect, and the addition of SV119 did 
not enhance the blocking effect (Figure 5B). However, 
chemical conjugation of the two components, SW V-49, 
resulted in a marked decrease in cystine internalization by 
the cancer cells. There was an 85% (SD: ± 2.7) blockade 
Figure 4: sW V-49 outperforms gemcitabine in stroma-dense models of pancreatic cancer. A. C57BL/6 mice (n = 5-6 mice/
group) with KP-2 orthotopic tumors were treated twice weekly with 20 mg/kg gemcitabine i.p. or with daily 200 nanomoles SW V-49 for 
two weeks once a palpable tumor had formed. Mice in the SW V-49 group had significantly smaller tumors compared to gemcitabine (***p 
= 0.0007) and vehicle (***p = 0.0003). b. C57BL/6 mice (n = 5 mice/group) with established KCKO tumors were treated twice weekly 
with 20 mg/kg gemcitabine i.p. or twice weekly with 200 nanomoles/injection SW V-49 i.p. for three weeks after tumors had grown to 5-6 
mm in diameter. Mice in the SW V-49 group had significantly smaller tumors compared to gemcitabine (p = 0.049) and vehicle (p = 0.047).
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with the conjugate compared to untreated cells. Compared 
to the mix of SV119 and Erastin (43 ± 2.5% blockade), 
we observed a 4-fold uptake reduction with the conjugate 
(Figure 5B, p = 0.004). We then assessed for ROS 
production to further confirm that the expected effector 
pathway of dm-Erastin was still functional with our 
conjugate. The strong effect of SW V-49 on the cystine/
glutamate antiporter correlated with ROS production. After 
AsPC-1 cells were treated, the production of intracellular 
ROS increased significantly only for SW V-49 (Figure 
5C, p < 0.0001). All other compounds, in isolation and as 
equimolar mixtures, did not result in elevated ROS levels 
Figure 5: sW V-49 competes for the sigma-2 receptor and enacts erastin-mediated death by inhibition of thesystem 
xc- cystine/glutamate antiporter leading to ros production that is reversible with n-acetylcysteine rescue. A. SW 
V-49 inhibits uptake of a fluorescently labeled sigma-2 ligand (SW120) in a dose-dependent manner. AsPC-1 cells were pretreated with 
increasing concentrations of SW V-49, followed by incubation with SW120 (10 nM), prior to analysis by flow cytometry. b. A cystine 
uptake assay was performed to assess the impact of the various compounds on the system xc
- antiporter. AsPC-1 cells were exposed for 
three minutes with SW V-49, SV119, Erastin, or an equimolar mix of SV119 and Erastin (200 µM). Uptake of 14C-labeled cystine was 
recorded by scintillography relative to DMSO treated control cells. Cystine uptake was reduced nearly 4-fold by 85% (SD: ± 2.7) in cells 
treated with SW V-49 compared to cells with an equimolar concentration of SV119 and Erastin (**p = 0.004). c. The production of ROS 
was measured as an indicator of effective Erastin-driven cytotoxic activity. AsPC-1 cells were treated with 8 µM of compound and ROS 
production was assayed one hour after treatment. Only SW V-49 treatment caused a ROS production level 1.5-fold (SD: ± 0.04 fold) higher 
than in all other treatment groups (****p < 0.0001). d. Addition of the antioxidant N-acetylcysteine (NAC) prevents SW V-49-mediated 
cell death (**p = 0.003). AsPC-1 cells were treated with NAC (10 mM) or vehicle and then exposed to SW V-49 (10 µM); NAC treatment 
rescued AsPC-1 cells from SW V-49.
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and were similar to DMSO-treated control cells (Figure 
5C). Cell death was completely abolished in the presence 
of the antioxidant N-acetyl cysteine (NAC) (Figure 5D, p 
= 0.003), further suggesting the ROS pathway is a major 
contributor of cancer cell death induced by SW V-49.
dIscussIon
Sigma-2 ligands have been shown to preferentially 
bind cancer cells [36], and we have previously described 
their capacity not only to image pancreatic cancers 
in animal models [15] but, even more importantly, in 
clinical imaging studies [37]. We and others have tested 
the safety of sigma-2 ligands and discovered that several 
of these compounds had intrinsic anti-cancer properties 
at high doses [17-19]. However, our observation that 
sigma-2 ligands were capable of internalizing additional 
drug cargoes provided the impetus for the development 
of more effective cancer-selective therapeutics [14, 
20]. Previously, we tested delivery of peptides and 
chemotherapeutic agents and found that some small 
molecules retain their mechanism of action and efficacy 
when conjugated to select sigma-2 ligands. In several 
instances, conjugation to a sigma-2 ligand also enhanced 
delivery and internalization of the drug cargo [20, 21].
Erastin exhibits features that make it an attractive 
cargo for sigma-2 ligand-mediated cancer cell delivery. 
Erastin was initially described as a potent cytotoxic drug 
against RAS mutant cancers [10], and as KRAS mutations 
are found in more than 90% of pancreatic cancer patients 
[38], we hypothesized that an Erastin-based therapy 
would work effectively if we could overcome the uptake 
blockade observed in pancreatic cancer cells. We found 
our conjugate to be effective in KRAS-mutant and KRAS-
wildtype pancreatic cancer cells. Subsequently, others 
have also found that the main mechanism of action for 
Erastin and its analogues is a non-apoptotic, oxidative 
form of cell death [7, 8]. We believe that our conjugate 
is so effective at generating ROS in cancer cells that it is 
impossible for us to differentiate subtle differences that 
might exist between KRAS-mutant and KRAS-wildtype 
cancers. 
Through chemical conjugation, we successfully 
converted an Erastin analogue into a potent, targeted 
therapeutic (SW V-49) for pancreatic cancer with minimal 
off-site toxicity. Conjugation of dm-Erastin with SV119 
overcame the internalization block that was observed 
in pancreatic cancer while preserving Erastin’s inherent 
anti-tumor activity. We successfully demonstrated 
cellular association and reduction from the extracellular 
environment (supernatant) of SW V-49, while dm-Erastin 
remained in the media, despite the presence of pancreatic 
cancer cells in the culture vessels. We demonstrated 
that SW V-49 competed for the sigma-2 receptor with 
another well-established sigma-2 ligand suggesting the 
delivery and internalization function was preserved in the 
conjugate. SW V-49 also proved to be highly effective in 
three-dimensional pancreatic cancer organoid cultures. 
Success in this experimental in vitro setting may better 
predict drug efficacy at clinically achievable drug 
concentrations due to the ability of the organoid cultures 
to reproduce relevant aspects of disease progression 
unachievable in standard in vitro cell culture experiments.
The most promising finding of our current study 
was the ability of SW V-49 to effectively target pancreatic 
cancer in multiple murine models with minimal toxicity. 
We demonstrated the strong therapeutic response in 
several immunocompetent syngeneic models, a patient-
derived xenograft model, and stroma-dense orthotopic 
models. Each of these models has features which 
recapitulate an aspect of the human disease and, taken 
together, we interpret success in all these models as a 
suggestion that SW V-49 has potential as a therapeutic for 
human pancreatic cancer. Only a short treatment interval 
with SW V-49 was required to reduce tumor sizes, delay 
tumor growth, and improve survival of our test animals. 
In addition, we found SW V-49 to be more effective in 
decreasing tumor burden than gemcitabine, a standard 
chemotherapeutic used clinically for pancreatic cancer. 
The cancer-selective delivery of SW V-49 may limit off-
site toxicity and this supposition is supported by normal 
complete blood counts and serum chemistries in treated 
mice as well as by pathologic examination at necropsy.
Finally, we demonstrated preserved function of the 
Erastin analogue in inhibiting the system xc
- antiporter 
[7]. Pancreatic cancer cells have been reported to 
upregulate expression of system xc
-[39], which leads 
to an enhanced capacity to import cystine, resulting in 
increased glutathione production. Here, we overcame 
the internalization block in pancreatic cancer and 
demonstrated a nearly 4-fold higher efficiency of SW 
V-49 than Erastin in inhibiting cystine uptake. This 
inhibition directly correlated with a robust increase in 
ROS production as quickly as one hour post-treatment 
and could be rescued by the antioxidant N-acetyl cysteine. 
In summary, pancreatic cancer is a devastating 
malignancy and novel treatment approaches are 
desperately needed. Targeted delivery and efficient 
internalization of small molecules to pancreatic cancer 
cells represents one of the key advantages of the sigma-2 
ligand-based drug concept. Tumor-selective delivery of the 
novel Erastin conjugate SW V-49 decreased tumor burden 
and increased survival while limiting off-site toxicities 
in preclinical mouse models of pancreatic cancer. Given 
the impressive findings using the best available models of 
pancreatic cancer explored in our current study, we believe 
further experimentation is highly warranted to rapidly 




The originally identified Erastin molecule [10] was 
purchased from EMD Millipore (Billerica, MA). Sigma-2 
ligand SV119 and Erastin analogue (dm-Erastin) were 
synthesized according to published methods [23, 40]. 
Synthesis of the sigma-2/dm-Erastin conjugate (SW V-49) 
is described in detail (Figure S1).
cell lines
The pancreatic cancer lines AsPC-1, BxPC-3, Mia 
PaCa-2, and PANC-1 were obtained from the American 
Type Culture Collection (ATCC, Manassas, VA). The 
synovial sarcoma cell line SYO-1 was provided by 
Dr. Van Tine. The mouse KCKO cell line isolated 
from a spontaneously developing pancreatic cancer 
overexpressing human MUC1 [27, 28] was kindly 
provided by Dr. Pinku Mukherjee (University of North 
Carolina, Charlotte, NC). The mouse KP-2 line was 
derived from pancreatic cancer tumor tissue obtained 
from p48-CRE/LSL-KrasG12D/p53flox/+ mice (backcrossed 
C57BL/6, n = 6). AsPC-1 and BxPC-3 cells were cultured 
in RPMI-1940 medium with 10% fetal bovine serum 
(FBS). MIA PaCa-2 cells were cultured in Dulbecco’s 
Modified Eagle’s Medium (DMEM) with 10% FBS and 
2.5% horse serum. PANC-1 and SYO-1 cells were cultured 
in DMEM with 10% FBS. KCKO cells were cultured in 
RPMI-1940 medium with 10% FBS, 1% sodium pyruvate, 
1% HEPES buffer, and 1% L-glutamine. KP-2 cells 
were cultured in 1:1 mixture of DMEM and Ham’s F-12 
Nutrient Mixture with 10% FBS. Penicillin (100 mg/mL) 
and streptomycin (100 mg/mL) were added to all media; 
cells were maintained in a humidified incubator at 37 ºC 
with 5% CO2. Cells were authenticated (every 6 months, 
last in October 2015) by morphology, doubling times, 
short tandem repeat profiling and tested for mycoplasma.
Efficacy studies of the targeted drug conjugate 
sW V-49 in vitro
Cancer cell lines (pancreatic or sarcoma) were 
plated at a density of 2 x 104 cells/well in black clear-
bottom 96-well plates for 24 hours prior to treatment. The 
cells were treated for 24 hours with their respective drugs 
(alone, in combination, or as a conjugate). Untreated cells 
served as a control. Cytotoxicity was evaluated employing 
a CellTiter-Glo Luminescent Cell Viability Assay 
(Promega, Madison, WI) [20]. Luminescence signals were 
recorded using a multi-mode microplate reader (BioTek 
instruments, Winooski, VT). Different drug concentrations 
were assayed in triplicates.
human pancreatic tumor organoid culture
Organoids were isolated and grown as previously 
described [41] and dissociated into single cells using 
TrypIE (Life Technologies). For each well of a 384-well 
plate, 500 cells were plated in 50 µL mixture of human 
complete organoid media [41] supplemented with 10% 
GFR-Matrigel (Corning) and 10 µM Rho Kinase inhibitor 
Y-27632 (Sigma). Twenty-four hours after plating, 50 µL 
human complete organoid media containing SW V-49, 
SV119, or dm-Erastin was dispensed. Cell viability 
was measured 72 hours post-treatment using CellTiter-
Glo Luminescent Cell Viability Assay. Experiment was 
replicated with cells from 5 different patients.
Mass spectrometry detection of sW V-49 and dm-
erastin in vitro
MIA PaCa-2 cells were plated at a density of 5 x 
105 cells/well in clear-bottom 6-well plates for 24 hours 
prior to treatment. The cells were exposed to 8 µM SW 
V-49 or dm-Erastin. After 2 hours, the supernatant was 
aspirated. The remaining cells were washed twice with 
phosphate buffered saline (PBS) and harvested with 
trypsin/EDTA buffer (Life Technologies, Grand Island, 
NY). Empty wells were used to test drug stability in media 
at 37 ºC. Samples were analyzed by mass spectrometry 
at the Proteomics & Mass Spectrometry Facility at the 
Donald Danforth Plant Science Center. Cell samples 
were extracted using 1 mL 1:1 acetonitrile/methanol then 
dried down and resuspended to 100 µL. Media samples 
were diluted 30x prior to injection. Compounds were 
analyzed using a 4000 QTRAP equipped with a Shimadzu 
Prominence UPLC with an injection volume of 20 µL 
using standard gradient and solvents. Experimentation was 
performed in triplicates.
In vivo assessment of sW V-49 in syngeneic and 
patient-derived xenograft models of pancreatic 
cancer
Animal studies were performed in adherence with 
the animal studies protocol approved by the Washington 
University Institutional Animal Care Facility. C57BL/6 
mice (6 weeks old, National Cancer Institute Laboratories) 
were injected in the right flank with 200 µL of a single-cell 
suspension of KCKO cells in RPMI medium (2.5 x 105 
cells per mouse). Treatment began when the mean tumor 
diameter was 5-6 mm. Mice received daily i.p. injections 
with 375 nanomoles SW V-49, SV119, dm-Erastin, or 
equimolar combination of SV119 and dm-Erastin in 100 
µL vehicle or vehicle alone (control) for 10 days. Vehicle 
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was a mixture of 25% Cremophor in H2O. Tumors were 
measured in two dimensions every other day with a digital 
caliper, and tumor volumes were calculated by the standard 
formula of Tumor Volume = Length x Width2 x 0.5. 
Several mice from each treatment cohort were assessed 
for pathologic evaluation (Digestive Diseases Research 
Core Center at our institution). Blood was collected for 
complete blood count (CBC) and biochemical analysis 
(AST, ALT, BUN, total protein, glucose and Cr). Organs 
were examined grossly and histologically. 
Surgical pancreatic adenocarcinoma specimens (3 
x 3 mm pieces) were implanted subcutaneously into the 
flanks of anesthetized NOD/SCID mice [29, 30]. Stable 
patient-derived xenograft (PDX) lines were obtained after 
passaging the tumors three times. These tumors were 
implanted subcutaneously into the right flanks of athymic 
female nude mice (6 weeks old, National Cancer Institute 
Laboratories), and treatment began when tumors reached 
5-6 mm in diameter. Mice were treated daily with i.p. 
injections of 375 nanomoles SW V-49 or control for 14 
days. For all survival experiments, mice were euthanized 
and considered dead when the tumors reached a diameter 
of 2 cm or had ulcerated. 
Syngeneic orthotopic pancreatic cancer tumors 
were established by surgical implantation. C57BL/6 mice 
(8 weeks old, Jackson Laboratory) were injected in the 
tail of the pancreas with 50 µL single-cell suspension 
of KP-2 cells (2.5 x 105 cells per mouse) in Matrigel 
(Corning). On day 7 gross palpation revealed a tumor 
and mice were treated twice weekly with i.p. injections 
of 20 mg/kg gemcitabine (Tocris) or daily with 200 
nanomoles SW V-49 for two weeks. Vehicle was used as a 
control. C57BL/6 mice (8 weeks old, Jackson Laboratory) 
were injected in the right flank with 100 µL single-cell 
suspension of KCKO cells (2.5 x 105 cells per mouse) in 
PBS to create a syngeneic subcutaneous model. Treatment 
began when the tumors reached 5-6 mm in diameter. Mice 
were treated twice weekly with i.p. injections of 20 mg/kg 
gemcitabine (Tocris) or 200 nanomoles SW V-49 for three 
weeks. Vehicle was used as control.
sW V-49 uptake studies by pancreatic cancer cells
AsPC-1 cells (5 × 105/well) were seeded into 6-well 
plates 24 hours before treatment. The cells were incubated 
for 30 minutes at 37°C with 0 (control), 10, 30 and 50 
μM of SW V-49 followed by addition of the fluorescently 
labeled sigma-2 ligand SW120 (10 nM). Thirty minutes 
after SW120 addition, the cells were washed twice with 
PBS and harvested with trypsin/EDTA buffer. The cells 
were washed twice with PBS, and SW120 internalization 
blockade by SW V-49 was determined by flow cytometry 
(FACSCalibur, BD Biosciences, San Jose, CA).
cystine uptake assay
Cystine uptake assay was performed as previously 
described [7]. Briefly, 5 x 105 AsPC-1 cells/well were 
seeded overnight in a 6-well plate. Cells were washed 
twice in pre-warmed Na+-free uptake buffer (137 mM 
choline chloride, 3 mM KCl, 1 mM CaCl2, 1 mM MgCl2, 
5 mM D-glucose, 0.7 mM K2HPO4, and 10 mM HEPES 
[pH 7.4]). Cells were incubated for 10 minutes at 37°C in 
1 mL of uptake buffer to deplete cellular amino acids. This 
buffer was replaced with 600 μL uptake buffer containing 
200 µM of compound (SW V-49, SV119, dm-Erastin, or 
an equimolar mix of SV119 and dm-Erastin) and 0.12 μCi 
(80 - 110 mCi/mmol) of L-[3,3′-14C]-cystine (American 
Radiolabeled Chemicals, St. Louis, MO) and incubated 
for 3 minutes at 37°C. DMSO was used as a control. 
Cells were washed three times with ice-cold uptake buffer 
and lysed in 500 μL of 0.1 M NaOH. To this lysate, 1 
mL of scintillation fluid was added and radioactive counts 
per minute were obtained using a scintillation counter 
(Beckman instruments, Fullerton, CA.). Experiment was 
performed in triplicates.
detection of reactive oxygen species (ros)
ROS measurement was performed using Total 
ROS/Superoxide Detection Kit (Enzo Life Sciences, 
Farmingdale, NY) according to the manufacturer’s 
instructions. Briefly, AsPC-1 cells were seeded at a 
density of 2 x 104 cells/well in black clear-bottom 96-well 
plates for 24 hours prior to treatment. Cells were treated 
with 8 µM SV119, Erastin, SW V-49, or an equimolar 
concentration of SV119 and Erastin. DMSO was used as 
a control. One hour post-treatment, culture supernatants 
were removed and replaced with 100 µL/well of ROS/
Superoxide Detection Mix reagent. Fluorescent signal was 
measured using a multi-mode microplate reader (Bio-Tek). 
The assay was performed in 6 replicates.
Inhibition of sW V-49-mediated ros production 
with n-acetyl cysteine
AsPC-1 cells were plated at a density of 2 x 104 
cells/well in opaque 96-well, clear-bottom plates 24 
hours prior to treatment. Cells were treated with N-acetyl 
cysteine (10 mM) or vehicle and exposed to SW V-49 (10 
µM) for 5 hours. CellTiter-Glo Luminescent Cell Viability 
Assay was performed. Assay was performed in triplicate.
statistical analyses
Statistical analyses and data plotting were 
performed using GraphPad Prism software version 6.03 
(San Diego, CA) in consultation with JL (biostatistician). 
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Results were expressed as mean ± standard error of the 
mean of at least 3 biological replicates. IC50 values were 
calculated by curve fitting normalized viability versus 
drug concentration. One-way ANOVA was used to analyze 
the differences in IC50 values and SW V-49 inhibition with 
NAC tests. Student’s two-tailed unpaired t-tests were 
used to evaluate the difference in SW V-49 tissue uptake, 
cystine uptake, ROS production, and tumor volume. 
Mann-Whitney test was used to compare the difference 
in CBC and biochemistry analyses. Kaplan-Meier 
survival analyses were used to assess differences between 
treatment groups and were compared using a log-rank 
test. Survival is reported as median survival ± standard 
deviation. Repeated measures ANOVA was used for 
analysis of tumor size. A p-value < 0.05 was considered 
significant for all analyses. 
Abbreviations
AST, aspartate aminotransferase; ALT, alanine 
aminotransferase; BUN, blood urea nitrogen; Cr, 
Creatinine; i.p, intraperitoneal; IC50, half maximal 
inhibitory concentration.
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